News
At Cell-Easy, we provide end-to-end GMP manufacturing services for advanced therapy medicinal products (ATMPs), with a strong focus on compliance, scalability, and reliability.
We help biotech and pharma companies bring innovative cell therapies from the lab to the clinic by combining high-quality starting material sourcing, robust process development, and clinical-grade GMP production that meets international standards (MHRA, ANSM, EMA, FDA readiness).
Whether you need early clinical batches or large-scale production, our tailored solutions optimize your process, minimize risks, and accelerate time-to-clinic.
Cell-Easy Launches an iPSC-Derived Beta Cell Program to Tackle Scale-Up Challenges
Learn more: Cell-Easy Launches an iPSC-Derived Beta Cell Program to Tackle Scale-Up ChallengesCell-Easy Launches an iPSC-Derived Beta Cell Program to Tackle Scale-Up Challenges Backed by a €12M Bpifrance grant, the program builds a GMP-compatible manufacturing platform for iPSC-derived cell therapies directly applicable to biotech and pharma iPSC programs. Toulouse, 2026 April 14th Tackling one of the main bottlenecks in iPSC-derived therapies Scale-up remains one of the most…
CHU Toulouse and Cell-Easy Launch A-MUSE, a Phase 1/2 Clinical Trial Evaluating the CellReady® Allogeneic MSC Platform in Systemic Sclerosis
Learn more: CHU Toulouse and Cell-Easy Launch A-MUSE, a Phase 1/2 Clinical Trial Evaluating the CellReady® Allogeneic MSC Platform in Systemic SclerosisCHU Toulouse and Cell-Easy Launch A-MUSE, a Phase 1/2 Clinical Trial Evaluating the CellReady® Allogeneic MSC Platform in Systemic Sclerosis Toulouse, January 22, 2026 — Cell-Easy, a CDMO specialized in the development and GMP manufacturing of Advanced Therapy Medicinal Products (ATMPs), announces a new clinical milestone achieved in close collaboration with Toulouse University Hospital (CHU Toulouse).…
CHU Toulouse and Cell-Easy Receive Regulatory Approval of A3D: A Phase 1 Trial Using CellReady® in Alzheimer’s Disease
Learn more: CHU Toulouse and Cell-Easy Receive Regulatory Approval of A3D: A Phase 1 Trial Using CellReady® in Alzheimer’s DiseaseCHU Toulouse and Cell-Easy Receive Regulatory Approval of A3D: A Phase 1 Trial Using CellReady® in Alzheimer’s Disease Cell-Easy, a Contract Development and Manufacturing Organization (CDMO) specialized in advanced cell therapies, announces that its allogeneic adipose-derived mesenchymal stem cell product, CellReady®, will be investigated in a newly approved Phase 1 clinical trial for Alzheimer’s disease.…
Cell-Easy Expands its GMP Cell Therapy Manufacturing Facility to Support Growing Client Demand
Learn more: Cell-Easy Expands its GMP Cell Therapy Manufacturing Facility to Support Growing Client DemandCell-Easy Expands its GMP Cell Therapy Manufacturing Facility to Support Growing Client Demand New state-of-the-art class-B cleanrooms, development labs, and logistics upgrades accelerate scalable production of autologous & allogeneic cell therapies in compliance with FDA/EMA standards. Cell-Easy, a leading European Contract Development and Manufacturing Organization (CDMO) specializing in cell therapy, today announced the expansion of its GMP…
CTA Approval to initiate ALLOFIST
Learn more: CTA Approval to initiate ALLOFISTCTA Approval to initiate ALLOFIST CHU Toulouse receives CTA Approval to initiate ALLOFIST, a Phase 1/2 Trial based on Cell-Easy’s proprietary adipose-derived MSC in Patients suffering from Crohn Disease. The long-term partnership between Cell-Easy and Toulouse University Hospital (CHU Toulouse) continues to bear fruits, bringing innovative MSC-based therapies to local patient cohorts. This time, it’s…
Mastering Cell Bank Development and Manufacturing Services for US Pharma company
Learn more: Mastering Cell Bank Development and Manufacturing Services for US Pharma companyMastering Cell Bank Development and Manufacturing Services for US Pharma company Cell-Easy Expands US Footprint with Key Contract Signing for Master Cell Bank (MCB) and Working Cell Bank (WCB) Manufacturing Services. Cell-Easy, a European Contract Development and Manufacturing Organization (CDMO) specializing in Cell Therapy, announces a significant milestone with the signing of a Cell Bank…